Akorn — Investor Presentation (September 2019)
21 slides from Akorn's investor presentation, Sep 10, 2019
Slide 1: Investor Presentation September 2019
INVESTOR PRESENTATION September 2019
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward - Looking Statements This presentation contains forward - looking statements, including statements regarding our stabilization, transformation, return to profitability, higher value opportunities, R&D investment targets, completion of cGMP improvements, quality syst
Slide 3: Akorn is executing a significant turnaround
Akorn is executing a significant turnaround 3 Initial steps have been taken to stabilize the business and focus on long - term profitable growth ▪ Strengthening the foundation and improving operational results ▪ Improving financial results and cash flow generation ▪ Increasing R&D efficiency and bol
Slide 4: Akorn Today
Akorn Today 4 Lake Forest, Illinois Company headquarters Diversified portfolio of generic, branded, over - the - counter (OTC) and animal health products Strong pipeline of pending ANDAs ~1800 employees globally 4 manufacturing facilities Product mix focused on alternate dosage forms Akorn is a lead
Slide 5: Experienced Leadership Team
Experienced Leadership Team 5 Douglas Boothe President and CEO 18 years in pharma. Prior experience: Impax, Perrigo, Actavis Duane Portwood EVP and CFO 4 years at Akorn . Prior experience: Home Depot, Wrigley, PwC Joseph Bonaccorsi EVP and General Counsel 17 years in healthcare, 10 at Akorn. Prior e
Slide 6: Foundation For Success
Foundation For Success 6 Fundamental strengths provide a growth platform upon which to build Diversified Product Portfolio Strong Growth Potential Operational Efficiencies Experienced Management Team Strong Product Pipeline and R&D Capabilities Favorable Market Dynamics
Slide 7: Diverse Specialty Pharma Portfolio
Generic Prescription Branded Ophthalmics Consumer Health Animal Health ▪ Broad and diverse portfolio of ~150 products ▪ Products across variety of alternative dosage forms ▪ High barriers to entry ▪ Strong presence in both retail and institutional markets ▪ Portfolio of OTC brands ▪ Flagship brand:
Slide 8: Strong R&D Pipeline
= Number of ANDAs Strong R&D Pipeline 36 pending ANDAs 1 represent a total market opportunity of ~$5.6B with significant diversification by dosage form 8 $72 $313 $1,109 $4,144 Topical Other Injectable Ophthalmic 17 9 6 4 • Development areas of focus: • High value ophthalmic suspensions and injectab
Slide 9: Favorable market dynamics with multiple tailwinds
Favorable market dynamics with multiple tailwinds Source: Company Management and IQVIA Loss of exclusivity of b rands driving generic opportunities 5 6 Generic substitution rates and prescription volume both steadily increasing 3 Savings to the US healthcare system from generics will continue to dri
Slide 10: Near-Term Priorities
10 Invest in New Product Development and Pipeline Stabilize and Improv e Operations • Stabilize and improve manufacturing, quality, and compliance while limiting new operational risks • Complete cGMP improvements across facilities • Target reductions in third - party spending • Increase level of ser
Slide 11: Operational Initiatives Begin to Yield Value
Operational Initiatives Begin to Yield Value 11 Early wins with operational performance and improved customer service Increased Product Availability Improved Operational Performance 4 Product Approvals 1 Expanded Organizational Capabilities Progressing with FDA Action Items at Decatur and Somerset 5
Slide 12: Facility Progress Update
Facility Progress Update Decatur Facility ▪ April / May 2018 FDA inspection resulted in OAI status ▪ Warning letter received in January 2019 x FDA Compliance related activities expected to be substantially complete in early 2020 ▪ Ongoing activities include: ▪ Comprehensive, independent assessments
Slide 13: Financial Overview
A specialty pharmaceutical company OAKORN Financial Overview
Slide 14: Stabilizing Financial Performance
Stabilizing Financial Performance 14 $ in millions 2019E revenue reflects guidance range provided on 8/1/19 in 2019 Q2 release. Revenue Revenue Guidance • Growth predominately driven by market exclusivity of e phedrine sulfate injection • Operating performance negatively impacted by: • Increased com
Slide 15: Recent Earnings Summary
Recent Earnings Summary In both Q1 and Q2 2019, Akorn has demonstrated sequential improvement in operating results Q4’18 Q1’19 Q2’19 15 Adjusted EBITDA, as defined by the Company, is calculated as follows: net (loss) income, (minus) plus: ( i ) interest income (expense), net (ii) provision (benefit)
Slide 16: Confidence in Business Turnaround Drives Guidance
LONGER TERM • Continued growth and margin improvement • Meaningful annualized cost reductions Longer term 2020 • Normalized Earnings power • Adjusted EBITDA 2 at least doubling from 2019 Confidence in Business Turnaround Drives Guidance 1 16 Net Loss : ($273) to ($258) million Net Revenue : $690 to
Slide 17: Investment Highlights
Investment Highlights Akorn is a leading specialty pharma player in attractive niche markets Diversified Product Portfolio Majority of Sales Are for Alternate Dosage Forms Strong Product Pipeline and R&D Capabilities Strong Growth Potential Experienced Management Team • Diversified portfolio not rel
Slide 18: Appendix
A specialty pharmaceutical company OAKORN Appendix
Slide 19: Recent Product Launches
Recent Product Launches Generic Name (Strength) Brand Reference Market $ M 1 Current # of Competitors Launched Ropivacaine Injection (0.2%) Naropin® $41 3 Jan - 19 TheraTears ® Sterilid ® Antimicrobial Sterilid ® n/a - Apr - 19 Dicyclomine Injection (10mg/mL) Bentyl® $18 4 Jun - 19 Loteprednol Etabo
Slide 20: Reconciliation of GAAP Net (Loss) to Non-GAAP EBITDA and Adjusted EBITDA
Reconciliation of GAAP Net (Loss) to Non - GAAP EBITDA and Adjusted EBITDA 1 20 Six Months Ended Three Months Ended Year Ended June 30, June 30, March 31, December 31, December 31, $ in thousands 2019 2019 2019 2018 2018 ($193,780) ($111,599) ($82,181) ($215,038) ($401,909) Depreciation expense 15,1
Slide 21: Reconciliation of GAAP Net (Loss) to Non-GAAP EBITDA and Adjusted EBITDA
Reconciliation of GAAP Net (Loss) to Non - GAAP EBITDA and Adjusted EBITDA 1 21 $ in millions Adjusted EBITDA, as defined by the Company, is calculated as follows: net (loss) income, (minus) plus: ( i ) interest income (expense), net (ii) provision (benefit) for income taxes (ii) depreciation and am